The AHA today commented on the Food and Drug Administration’s draft guidance for industry and FDA staff on clinical decision support software as part of the agency’s efforts to implement Section 3060(a) of the 21st Century Cures Act. AHA expressed concern that “FDA’s interpretation of certain criteria could result in many existing CDS algorithms being subject to the FDA approval process and ultimately slow the pace of innovation and development of new algorithms to support better patient care and outcomes.” In its letter, AHA shared specific recommendations with FDA and said it “looks forward to working with the FDA to ensure the agency’s regulatory approach to implementing Section 3060(a) is consistent with the language and intent of the Cures Act and prioritizes patient safety while at the same time allowing hospitals and health systems to continue to implement innovative decision support tools.”

Related News Articles

Headline
The Food and Drug Administration today released for comment its first plan for advancing oversight of medical software based on artificial intelligence and…
Headline
CHI Health and Creighton University Medical Center, an academic medical center in Omaha, Neb., partnered to design and build University Clinic, a new primary…
Headline
The International Code Council has named Jonathan Flannery, senior associate director of advocacy for the AHA’s American Society for Health Care Engineering,…
Headline
“Achieving health equity is a journey,” write Priya Bathija, AHA vice president of strategic initiatives, and Julia Resnick, senior program manager. To bridge…
Blog
The COVID-19 pandemic has placed spotlight on health inequities in the United States. It has illuminated that, regardless of access to health care services,…
Headline
AHA’s The Value Initiative is providing new resources to support hospitals’ and health systems’ efforts to adopt hospital-at-home care for patients who…